A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
https://european-biotechnology.com/wp-content/uploads/2024/04/HIV_Christian_Eggeling_Foto_Jan-Peter_Kasper_FSU_40d3247028.jpg600941Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-10-04 10:49:132019-10-04 10:49:13New method allows tracking of HIV
How can biotechnology and bioeconomy contribute to establish a sustainable and circular economy? Nearly 500 attendees discussed latest trends at EFIB 2019 in Brussels.
H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/Asebio_Investor_Day_2019.jpg558992Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-10-01 08:15:002019-10-01 08:15:00Spanish sector attracting more and more investment
Edwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2019-09-30 13:25:002019-09-30 13:25:00Lytix Biopharma: Rekdal returns as CEO
Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority pathogen N. gonorrhoea.
British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
BASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.
New method allows tracking of HIV
Latest NewsA new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Successful EFIB in Brussels
Latest NewsHow can biotechnology and bioeconomy contribute to establish a sustainable and circular economy? Nearly 500 attendees discussed latest trends at EFIB 2019 in Brussels.
Rottapharm Biotech: POC in osteoarthritis pain
Latest NewsRottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
H.E.L. Group: Realising market potential
AppointmentsH.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.
Spanish sector attracting more and more investment
Latest NewsCreoptix AG closes CHF8m financing round
Latest NewsSwiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
Lytix Biopharma: Rekdal returns as CEO
AppointmentsEdwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.
AMR: GARDP and Entasis Therapeutics start pivotal study
Latest NewsJane Osbourn joins Mogrify Board
AppointmentsBritish cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
BASF broadens biotech business by Isobionics acquisition
Latest NewsBASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.